Efficacy and Safety of Moderate-Dose Glucocorticoids with Tacrolimus in High-Risk Membranous Nephropathy: A Real-World Comparison of Three Immunosuppressive Regimens.
- 1Department of Nephrology, the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
- 2Department of Integrated Traditional Chinese and Western Medicine, Liaoning University of Traditional Chinese Medicine Xinglin College, Shenyang, Liaoning, People's Republic of China.
- 3Laboratory of Epigenetics, School of Life Sciences, China Medical University, Shenyang, Liaoning, People's Republic of China.
Abstract
This study was designed to evaluate the efficacy of moderate-dose glucocorticoid (mGC) combined with tacrolimus (FK506) in high-risk patients with membranous nephropathy (MN), and compare with two widely used therapies: full-dose glucocorticoid (GC) plus cyclophosphamide (CTX), and rituximab (RTX) plus FK506, the latter being recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines. This study aims to provide evidence for individualized treatment in high-risk MN. A total of 154 patients with high-risk MN were enrolled and assigned into three treatment groups: full-dose GC combined with CTX group (GC+CTX) (n=53), mGC combined with FK506 group (mGC+FK506) (n=51), and RTX combined with FK506 group (RTX+FK506) (n=50). Baseline clinical and laboratory parameters and follow-up data at 1, 3, 6, and 12 months post-treatment were collected. Outcomes including disease remission rates, relapse rates, and adverse events were compared among the three groups. At 12 months of follow-up, the overall remission rates for the GC+CTX, mGC+FK506, and RTX+FK506 groups were 94.4%, 94.1%, and 82.0%, respectively, with corresponding complete remission rates of 32.1%, 43.1%, and 24.0%. No significant intergroup differences were observed (P > 0.05). The mGC+FK506 group demonstrated higher remission rates at both 3 and 6 months. Multivariate Cox regression indicated that baseline serum albumin > 20 g/L was a protective factor (HR = 1.638, P = 0.004), and comorbid diabetes mellitus an independent risk factor (HR = 0.617, P = 0.032). The mGC+FK506 regimen was non-inferior to the GC+CTX and RTX+FK506 regimens in treating high-risk MN, with an earlier onset of therapeutic effect and superior remission rates at 3 and 6 months. Early correction of hypoalbuminemia and strict glycemic control are critical for improving prognosis. This study may provide evidence for individualized treatment selection in high-risk MN patients who are intolerant to high-dose GC or have limited access to RTX.
Related
- Efficacy of immunosuppressive therapy in low-risk and intermediate- risk idiopathic membranous nephropathy patients : a 2-year follow-up study
- Influence of Occupational Exposures on Cytokine Profiles in Patients with Membranous Nephropathy
- A case of recurrent membranous nephropathy with multiple necrotizing pulmonary nodules
- Sustained remission of NELL-1-positive membranous nephropathy after lung adenocarcinoma resection and during subsequent atezolizumab therapy in a 68-year-old man: a case report
- Cronkhite-Canada Syndrome Associated with Primary Cutaneous Peripheral T-cell Lymphoma and Membranous Nephropathy: A Case Report
BibTeX
@article{sui2026efficacy,
title = {{Efficacy and Safety of Moderate-Dose Glucocorticoids with Tacrolimus in High-Risk Membranous Nephropathy: A Real-World Comparison of Three Immunosuppressive Regimens.}},
author = {Lu Sui and Yutong Ma and Xintian Yu and Yilin Meng and Xuqi Cui and Hao Geng and Jian Zhang and Xiao Bai and Weihao Shang and Li Sun},
journal = {Drug design, development and therapy},
year = {2026},
month = oct,
doi = {10.2147/dddt.s639867},
url = {https://europepmc.org/article/MED/42953776},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Efficacy and Safety of Moderate-Dose Glucocorticoids with Tacrolimus in High-Risk Membranous Nephropathy: A Real-World Comparison of Three Immunosuppressive Regimens.
AU - Lu Sui
AU - Yutong Ma
AU - Xintian Yu
AU - Yilin Meng
AU - Xuqi Cui
AU - Hao Geng
AU - Jian Zhang
AU - Xiao Bai
AU - Weihao Shang
AU - Li Sun
PY - 2026
DA - 2026/10/24
JO - Drug design, development and therapy
DO - 10.2147/dddt.s639867
UR - https://europepmc.org/article/MED/42953776
AB - This study was designed to evaluate the efficacy of moderate-dose glucocorticoid (mGC) combined with tacrolimus (FK506) in high-risk patients with membranous nephropathy (MN), and compare with two widely used therapies: full-dose glucocorticoid (GC) plus cyclophosphamide (CTX), and rituximab (RTX) plus FK506, the latter being recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines. This study aims to provide evidence for individualized treatment in high-risk MN. A total of 154 patients with high-risk MN were enrolled and assigned into three treatment groups: full-dose GC combined with CTX group (GC+CTX) (n=53), mGC combined with FK506 group (mGC+FK506) (n=51), and RTX combined with FK506 group (RTX+FK506) (n=50). Baseline clinical and laboratory parameters and follow-up data at 1, 3, 6, and 12 months post-treatment were collected. Outcomes including disease remission rates, relapse rates, and adverse events were compared among the three groups. At 12 months of follow-up, the overall remission rates for the GC+CTX, mGC+FK506, and RTX+FK506 groups were 94.4%, 94.1%, and 82.0%, respectively, with corresponding complete remission rates of 32.1%, 43.1%, and 24.0%. No significant intergroup differences were observed (P > 0.05). The mGC+FK506 group demonstrated higher remission rates at both 3 and 6 months. Multivariate Cox regression indicated that baseline serum albumin > 20 g/L was a protective factor (HR = 1.638, P = 0.004), and comorbid diabetes mellitus an independent risk factor (HR = 0.617, P = 0.032). The mGC+FK506 regimen was non-inferior to the GC+CTX and RTX+FK506 regimens in treating high-risk MN, with an earlier onset of therapeutic effect and superior remission rates at 3 and 6 months. Early correction of hypoalbuminemia and strict glycemic control are critical for improving prognosis. This study may provide evidence for individualized treatment selection in high-risk MN patients who are intolerant to high-dose GC or have limited access to RTX.
SN - 1177-8881
ER -